Ligand Pharmaceuticals (LGND) Announces $2M Milestone Payment, Affirms 2012 Revenue Guidance
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $286.29 -0.38%
Financial Fact:
Total revenues: 21.62M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Total revenues: 21.62M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will receive a $2 million milestone payment from Merck, known as MSD outside the United States and Canada, under the terms of a development and license collaboration for the development of dinaciclib.
Ligand is also affirming its previous 2012 revenue forecast of $30 million. However, the company now sees third quarter revenue of approximately $6 million, versus earlier guidance of approximately $8 million, and revenue in the fourth quarter now projected to be approximately $13 million, versus earlier guidance of approximately $11 million.
Ligand is also affirming its previous 2012 revenue forecast of $30 million. However, the company now sees third quarter revenue of approximately $6 million, versus earlier guidance of approximately $8 million, and revenue in the fourth quarter now projected to be approximately $13 million, versus earlier guidance of approximately $11 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Sigma Lithium resumes full operations after signing TAC agreement
- Nuvectis Pharma (NVCT) files $200M mixed shelf
Create E-mail Alert Related Categories
Corporate News, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
